Vnitr Lek 2013, 59(1):5-12

Targeted therapeuticts and their role in the treatment of internal diseases

P. Klener
I. interní klinika 1. lékařské fakulty UK a VFN a ÚHKT Praha, přednosta prof. MUDr. Marek Trněný, CSc.

Targeted therapy is a conceptual notion that should be used for such a treatment approach that has been developed based upon the known pathophysiology and/or biomarkers of a particular disease, mainly malignancies. Monoclonal antibodies and tyrosine-kinase inhibitors were among the first molecularly targeted agents. Monoclonal antibodies approach is based on targeting a biomarker expressed either on the surface of cancer cells or targeting different cytokines. Tyrosin-kinase inhibitors are directed at the druggable molecule involved in the cancer pathophysiology inhibiting aberrant tyrosin-kinase activity. Classification of targeted drugs and their use in the clinical practice is shortly reviewed.

Keywords: targeted therapy; monoclonal antibodies; tyrosin-kinase inhibitors; classification; clinical use

Received: January 3, 2013; Published: January 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klener P. Targeted therapeuticts and their role in the treatment of internal diseases. Vnitr Lek. 2013;59(1):5-12.
Download citation

References

  1. Airley R. Cancer chemotherapy. Willey-Blackwell, Oxford 2009.
  2. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. Appleton and Lange, Norwalk, 1994.
  3. Klener P. Klinická onkologie.Praha: Galén-Karolinum 2002.
  4. Mladosievičová B et al. Molekulové mechanizmy patogenézy nádorov. Bratislava: SAP 2011, 123 s.
  5. Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008; 35: 439-448. Go to original source... Go to PubMed...
  6. Mayer J, Klamová H, Žáčková D et al. Imatinib v první linii léčby s nově diagnostikovanou chronickou myeloidní leukemií v chronické fázi. Transfuze Hematol Dnes 2008; 15: 150-158.
  7. Klener P, Klener jr. P. Nová protinádorová léčiva a léčebné strategie v onkologii. Praha: Grada Publishingh 2010.
  8. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth fractor (VEGF) inhibition - a critical review. Anticancer agents Med Chem 2007; 7:223-245. Go to original source... Go to PubMed...
  9. Hartman JT, Haap M, Koop HG et al. Tyrosine kinase inhibitors - a review on pharmacology metabolism and side effects. Curr Drug Metab 2009; 10: 470-481. Go to original source... Go to PubMed...
  10. Wong MK, Lo AL, Lam B et al. Erlotinib as a salvage treatment after failure of first line gefitinib in non small cell lung cancer. Cancer Chemother Pharmacol 2009; 64: 656-663.
  11. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974. Go to original source... Go to PubMed...
  12. Chan S. Targeting the mammalian target of rapamycin (m-TOR): a new approach to treating cancer. Br J Cancer 2004; 25: 1420-1424. Go to original source... Go to PubMed...
  13. Klener P, Klener jr. P. ABL1, SRC a další nereceptorové proteinkinázy jako nové cíle specifické protinádorové terapie. Klin Onkol 2010; 23: 203-209. Go to PubMed...
  14. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol 2005; 23: 1147-1157. Go to original source... Go to PubMed...
  15. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Natur Rev 2010; 10: 317-327. Go to original source... Go to PubMed...
  16. Belada D. Monoklonální protilátky v léčbě lymfomů. Remedia 2008; 6: 416-423.
  17. Tazi L, Nafil H, Mahmal L. Monoclonal antibodies in hematological malignancies: past, present and future. J Cancer Res Ther 2012; 7: 309-407. Go to original source...
  18. Castillo J, Winer E, Quinsberry O. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36: 755-768. Go to original source... Go to PubMed...
  19. Palácová M. Trastuzumab. Remedia 2009; 20: 4-13.
  20. Van Cutsem E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 2009; 369: 1408-1417. Go to original source... Go to PubMed...
  21. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumor activity. Cancer 2008; 8: 579-591. Go to original source...
  22. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823-830. Go to original source... Go to PubMed...
  23. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature rev 2010; 10: 301-316. Go to original source... Go to PubMed...
  24. Choy EHS, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Brit J Rhematol 1998; 37: 484-490. Go to original source... Go to PubMed...
  25. Yuvienco C, Schwartz S. Monoclonal antibodies in rheumatic diseases. Med Health/Rhode Island 2011; 94: 320-324.
  26. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease. Gastroenteology 2006; 130: 323-333. Go to original source... Go to PubMed...
  27. Kelly RJ, Hill A, Arnold LM et al. Long-term treatment with eculimumab in paroxaysmal nocturnal hemoglobinuria. Blood 2011; 117: 6786-6792. Go to original source... Go to PubMed...
  28. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-904. Go to original source... Go to PubMed...
  29. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154-169. Go to original source... Go to PubMed...
  30. Kontermann RF. Recombinant bispecific antibodies for cancer. Acta Pharmacol 2005; 26: 1-9. Go to original source... Go to PubMed...
  31. Goldenberg DM, Cardillo IM, Shi V et al. Bispecific anti CD20/22 antibodies inhibit B-cell lymphoma proliferation by unique mechanism of action. Blood 2008; 111: 2211-2219. Go to original source... Go to PubMed...
  32. Nelson AI, Reichert JM. Development trends for therapeutic antibody fragments. Nature Biotechnol 2009; 27: 331-337. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.